These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25062506)

  • 21. Synthesis of tripeptides containing D-Trp substituted at the indole ring, assessment of opioid receptor binding and in vivo central antinociception.
    De Marco R; Bedini A; Spampinato S; Gentilucci L
    J Med Chem; 2014 Aug; 57(15):6861-6. PubMed ID: 25051243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer.
    Mitch CH; Quimby SJ; Diaz N; Pedregal C; de la Torre MG; Jimenez A; Shi Q; Canada EJ; Kahl SD; Statnick MA; McKinzie DL; Benesh DR; Rash KS; Barth VN
    J Med Chem; 2011 Dec; 54(23):8000-12. PubMed ID: 21958337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differentiation of delta, mu, and kappa opioid receptor agonists based on pharmacophore development and computed physicochemical properties.
    Filizola M; Villar HO; Loew GH
    J Comput Aided Mol Des; 2001 Apr; 15(4):297-307. PubMed ID: 11349813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
    Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
    Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Electrophysiological demonstration of mu, delta and kappa opioid receptors in the ventral pallidum.
    Mitrovic I; Napier TC
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1260-70. PubMed ID: 7891342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism.
    Balboni G; Salvadori S; Guerrini R; Negri L; Giannini E; Bryant SD; Jinsmaa Y; Lazarus LH
    J Med Chem; 2004 Jul; 47(16):4066-71. PubMed ID: 15267245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scouting new sigma receptor ligands: Synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives.
    Franchini S; Battisti UM; Prandi A; Tait A; Borsari C; Cichero E; Fossa P; Cilia A; Prezzavento O; Ronsisvalle S; Aricò G; Parenti C; Brasili L
    Eur J Med Chem; 2016 Apr; 112():1-19. PubMed ID: 26874044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
    Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
    J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peptide opioid antagonist separates peripheral and central opioid antitransit effects.
    Shook JE; Pelton JT; Hruby VJ; Burks TF
    J Pharmacol Exp Ther; 1987 Nov; 243(2):492-500. PubMed ID: 2824748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonpeptide analogues of dynorphin A(1-8): design, synthesis, and pharmacological evaluation of kappa-selective agonists.
    Ronsisvalle G; Pasquinucci L; Pittalà V; Marrazzo A; Prezzavento O; Di Toro R; Falcucci B; Spampinato S
    J Med Chem; 2000 Aug; 43(16):2992-3004. PubMed ID: 10956208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
    Grundt P; Jales AR; Traynor JR; Lewis JW; Husbands SM
    J Med Chem; 2003 Apr; 46(8):1563-6. PubMed ID: 12672258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities.
    Lattanzi R; Spetea M; Schüllner F; Rief SB; Krassnig R; Negri L; Schmidhammer H
    J Med Chem; 2005 May; 48(9):3372-8. PubMed ID: 15857143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and Synthesis of Enantiomerically Pure Decahydroquinoxalines as Potent and Selective κ-Opioid Receptor Agonists with Anti-Inflammatory Activity in Vivo.
    Soeberdt M; Molenveld P; Storcken RP; Bouzanne des Mazery R; Sterk GJ; Autar R; Bolster MG; Wagner C; Aerts SN; van Holst FR; Wegert A; Tangherlini G; Frehland B; Schepmann D; Metze D; Lotts T; Knie U; Lin KY; Huang TY; Lai CC; Ständer S; Wünsch B; Abels C
    J Med Chem; 2017 Mar; 60(6):2526-2551. PubMed ID: 28218838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. dextro- and levo-morphine attenuate opioid delta and kappa receptor agonist produced analgesia in mu-opioid receptor knockout mice.
    Wu HE; Sun HS; Terashivili M; Schwasinger E; Sora I; Hall FS; Uhl GR; Tseng LF
    Eur J Pharmacol; 2006 Feb; 531(1-3):103-7. PubMed ID: 16445907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripherally restricted opioid agonists as novel analgesic agents.
    DeHaven-Hudkins DL; Dolle RE
    Curr Pharm Des; 2004; 10(7):743-57. PubMed ID: 15032700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and synthesis of novel opioid ligands with an azabicyclo[2.2.2]octane skeleton having a 7-amide side chain and their pharmacologies.
    Watanabe Y; Kitazawa S; Nemoto T; Hirayama S; Iwai T; Fujii H; Nagase H
    Bioorg Med Chem; 2013 Jun; 21(11):3032-50. PubMed ID: 23623711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.
    Valenzano KJ; Miller W; Chen Z; Shan S; Crumley G; Victory SF; Davies E; Huang JC; Allie N; Nolan SJ; Rotshteyn Y; Kyle DJ; Broglé K
    J Pharmacol Exp Ther; 2004 Aug; 310(2):783-92. PubMed ID: 15054115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Dmt-D-Lys-Phe-Phe-OH as a highly antinociceptive tetrapeptide metabolite of the opioid-neurotensin hybrid peptide PK20.
    Kleczkowska P; Bojnik E; Leśniak A; Kosson P; Van den Eynde I; Ballet S; Benyhe S; Tourwé D; Lipkowski AW
    Pharmacol Rep; 2013; 65(4):836-46. PubMed ID: 24145077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and Pharmacological Evaluation of Fluorinated Quinoxaline-Based κ-Opioid Receptor (KOR) Agonists Designed for PET Studies.
    Tangherlini G; Börgel F; Schepmann D; Slocum S; Che T; Wagner S; Schwegmann K; Hermann S; Mykicki N; Loser K; Wünsch B
    ChemMedChem; 2020 Oct; 15(19):1834-1853. PubMed ID: 33448685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and pharmacological evaluation of [(3)H]HS665, a novel, highly selective radioligand for the kappa opioid receptor.
    Guerrieri E; Mallareddy JR; Tóth G; Schmidhammer H; Spetea M
    ACS Chem Neurosci; 2015 Mar; 6(3):456-63. PubMed ID: 25496417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.